Evidence map›Paper›PMID 34914062›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Development of the Antileishmanial Vaccine.

Sunil Kumar, Shubhranshu Zutshi, Mukesh Kumar Jha, Prashant Chauhan, Bhaskar Saha

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sunil Kumar *National Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, India.
Shubhranshu Zutshi *National Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, India.
Mukesh Kumar JhaNational Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, India.
Prashant ChauhanNational Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, India.
Bhaskar SahaNational Centre for Cell Science, Ganeshkhind, Pune, Maharashtra, India. bhaskar211964@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Search for an efficacious antileishmanial vaccine has led to clinical trials of numerous vaccine candidates in the past few decades. As no promising candidate has emerged from these studies, novel vaccine modalities and vaccine assessment techniques are still emerging for antileishmanial vaccine development. Briefly, this chapter discusses: (a) history and timeline of antileishmanial vaccine development; (b) techniques utilized for developing whole-parasite and subunit-based antileishmanial vaccine formulations, and (c) immunogenicity and post-challenge protective efficacy assessment of vaccine candidates.

Indexed as

Vaccine DevelopmentAntiprotozoal AgentsVaccines, SubunitAntiprotozoal AgentsVaccines, SubunitAntileishmanial vaccineElectroporationFlow cytometryImmunogenicityMass spectrometryNi-NTA affinity chromatographyParasite loadT-helper response

Identifiers

PMID34914062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.